IDEXX Laboratories, Inc. vs Johnson & Johnson — Stock Comparison
IDEXX Laboratories, Inc. (IDXX) and Johnson & Johnson (JNJ) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
IDEXX Laboratories, Inc. scores ahead of Johnson & Johnson on Q·Score (7.8 vs 7 out of 10), led by Growth (7.9 vs 5) and Valuation (7.9 vs 6.5). Johnson & Johnson scores higher on Sentiment, reflecting stronger analyst and market sentiment. Analyst consensus targets imply greater upside for IDXX (+36.8%) than for JNJ (+4.0%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
High-quality business with 74% return on equity and 25% profit margins.
High-quality business with 26% return on equity and 21% profit margins.
⚠ earnings contracting 1% year-over-year.
Analyst Consensus
Fundamentals
Frequently Asked Questions
IDXX vs JNJ: which stock scores better overall?
Based on Q·Score, IDEXX Laboratories, Inc. (IDXX) scores 7.8/10 versus Johnson & Johnson (JNJ) at 7/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: IDXX or JNJ?
IDEXX Laboratories, Inc. (IDXX) scores higher on Growth (7.9/10 vs 5/10). IDEXX Laboratories, Inc. reports revenue growth (9.7% YoY) while Johnson & Johnson reports (6.6% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is IDXX or JNJ more attractively valued?
IDEXX Laboratories, Inc. (IDXX) scores higher on Valuation (7.9/10 vs 6.5/10). IDXX trades at 30.5× P/E versus JNJ at 21.8×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about IDXX vs JNJ?
There are 13 analysts covering IDXX with a consensus price target of $698.92, and 22 analysts covering JNJ with a consensus target of $277.91. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: IDXX or JNJ?
IDEXX Laboratories, Inc. (IDXX) scores higher on Quality (9.3/10 vs 9.3/10). Net profit margin: IDXX at 25.0%, JNJ at 21.5%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: IDXX or JNJ?
IDEXX Laboratories, Inc. (IDXX) scores higher on Financial Health (7/10 vs 6.5/10). Market beta: IDXX at 1.54, JNJ at 0.23. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of IDXX and JNJ?
IDEXX Laboratories, Inc. (IDXX) has a market capitalisation of $40.2B, while Johnson & Johnson (JNJ) has a market cap of $643.9B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do IDXX or JNJ pay dividends?
IDXX does not currently pay a dividend, while JNJ pays a dividend yield of 2.01%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →